8-K: ALX Oncology Raises $150M in Equity Offering

ALX Oncology Holdings Inc. announced the pricing of an underwritten offering of common stock and pre-funded warrants, expecting to raise approximately $150 million to fund clinical development.

Summary

• ALX Oncology Holdings Inc. priced an underwritten offering of 76,979,112 shares of common stock at $1.57 per share.
• Additionally, 18,574,120 pre-funded warrants were sold at an offering price of $1.569 per warrant, with an exercise price of $0.001 per share.
• The gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and other estimated offering expenses, and excluding the exercise of any pre-funded warrants.
• All shares of common stock and pre-funded warrants in the offering are being sold by ALX Oncology.
• The offering is expected to close on February 2, 2026, subject to customary closing conditions.
• The financing was led by new investors RA Capital Management and TCGX, with participation from additional new and existing investors, including 5AM Ventures, Blackstone Multi-Asset Investing, Coastlands Capital, Driehaus Capital Management, HBM Healthcare Investments, Marshall Wace, OrbiMed, Redmile Group, venBio Partners, and Vivo Capital.
• The net proceeds are anticipated to fund the continued clinical development of evorpacept and its ALX2004 program, related clinical trials, and for working capital and other general corporate purposes.
• Directors and officers of the company are subject to a 60-day lock-up period following the date of the prospectus.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a net positive development for ALX Oncology, as it successfully secures substantial funding to advance its critical clinical pipeline. The strong institutional investor participation underscores confidence in the company's long-term prospects, despite the inherent dilution from the equity raise.

Positives

• Secured approximately $150 million in gross proceeds, significantly strengthening the company's financial position to advance its pipeline.
• Strong investor participation, including new investors like RA Capital Management and TCGX, alongside several existing institutional investors, indicates confidence in the company's prospects.
• The offering price of $1.57 per share for common stock matched the closing price on January 29, 2026, suggesting market acceptance of the pricing.
• Proceeds are specifically allocated to fund the continued clinical development of key therapeutic candidates, evorpacept and ALX2004, supporting future growth and potential value creation.

Negatives

• The issuance of 76,979,112 shares of common stock and pre-funded warrants to purchase an additional 18,574,120 shares will result in significant dilution for existing shareholders.
• The offering price of $1.57 per share reflects the current market valuation, which may be lower than previous highs, impacting existing shareholders' per-share value.

Risks

• Actual results or developments may differ materially from forward-looking statements due to various risks and uncertainties.
• Risks and uncertainties are related to the completion of the public offering on the anticipated terms or at all.
• Market conditions could impact the offering's success or terms.
• The satisfaction of customary closing conditions related to the offering is not guaranteed.
• More information about the risks and uncertainties faced by the company is contained under the caption 'Risk Factors' in its Quarterly Report on Form 10-Q filed with the SEC on November 7, 2025.

Future Outlook

ALX Oncology anticipates using the net proceeds from the offering to fund the continued clinical development of evorpacept and its ALX2004 program and related clinical trials, as well as for working capital and other general corporate purposes. The company cautions that actual results may differ materially from these forward-looking statements due to market conditions and the satisfaction of customary closing conditions related to the offering.

Management Comments

• ALX Oncology Holdings Inc. (ALX Oncology, Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients lives, today announced the pricing of an underwritten offering of common stock and pre-funded warrants.

Industry Context

StockSavvy.ai notes that this capital raise by ALX Oncology is consistent with the typical financing strategies of clinical-stage biotechnology companies, which frequently rely on equity offerings to fund extensive and costly research and development, particularly for ongoing clinical trials in oncology. The participation of prominent healthcare-focused investors like RA Capital Management, TCGX, OrbiMed, and HBM Healthcare Investments signals continued investor confidence in the long-term potential of novel cancer therapies and ALX Oncology's pipeline, despite the dilutive nature of such offerings.

Comparison to Industry Standards

• The filing does not provide specific comparable company, project, or result data to assess against global benchmarks.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new shares and warrants. However, the capital raise provides crucial funding for clinical programs, potentially increasing long-term value if trials are successful.
• Employees: Continued funding for research and development and clinical trials supports job security and potential growth opportunities within the company.
• Customers (Patients): The funding directly supports the advancement of novel cancer therapies (evorpacept, ALX2004), potentially leading to new treatment options and improved patient outcomes.
• Creditors: The capital raise strengthens the company's balance sheet, potentially reducing financial risk for creditors by improving liquidity and funding long-term projects.

Next Steps

• Expected closing of the offering on February 2, 2026.
• Continued clinical development of evorpacept in multiple cancer indications.
• Continued Phase 1 dose-escalation trial of ALX2004 in patients with EGFR-expressing solid tumors.

Key Dates

Recommendation

While the capital raise provides essential funding for ALX Oncology's clinical pipeline and demonstrates investor confidence, the significant dilution from the issuance of new shares and warrants warrants a 'hold' recommendation. Investors should monitor the progress of the clinical trials and the efficient deployment of the raised capital before considering further investment, as the long-term value creation hinges on successful clinical outcomes.

Keywords

ALX Oncology, ALXO, Underwritten Offering, Common Stock, Pre-Funded Warrants, Capital Raise, Biotechnology, Cancer Therapy, Clinical Development, Evorpacept, ALX2004, SEC Filing, Equity Financing, Oncology